{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:00:27Z","timestamp":1773820827729,"version":"3.50.1"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2020,4,10]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> We hypothesized that bevacizumab will potentiate activity of pembrolizumab. We conducted a phase Ib\/II, single-arm, multisite clinical trial of the combination in metastatic renal cell carcinoma (RCC). <\/jats:p><\/jats:sec><jats:sec><jats:title>PATIENTS AND METHODS<\/jats:title><jats:p> Patients with metastatic clear cell RCC who experienced progression after at least one systemic therapy (phase Ib) or were treatment na\u00efve (phase II) were enrolled. In phase Ib, pembrolizumab (200 mg) and bevacizumab (10 or 15 mg\/kg) were given intravenously every 3 weeks. The primary end point for phase II was overall response rate (ORR). With an 80% statistical power and a type I error probability of 0.1, 48 patients were to be accrued to detect an ORR of 42%. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Thirteen patients (ages 33-68 years; median, 55 years) were enrolled in the phase Ib study. No dose-limiting toxicities were reported. Pembrolizumab 200 mg and bevacizumab 15 mg\/kg were chosen for phase II. Forty-eight patients (ages 42-84 years; median age, 61 years; 33 males) were accrued for the phase II study. The primary end point was met, with the ORR reaching 60.9% (95% CI, 45.4% to 74.9%), consisting of 1 complete response (CR), 2 CRs in target lesions, 25 partial responses, 18 responses of stable disease, 2 unevaluable responses. Median progression-free survival was 20.7 months (95% CI, 11.3 to 27.4 months). Median overall survival was not reached at the median follow-up of 28.3 months. The most common treatment-related grade 3 toxicities were hypertension and proteinuria. There were two grade 4 toxicities: duodenal ulcer and hyponatremia. Presence of tumor-infiltrating T cells, but not programmed death-ligand 1 expression, in tumor tissue correlated with response. <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> The combination of 200 mg of pembrolizumab and a 15 mg\/kg dose of bevacizumab given every 3 weeks is safe and active in metastatic RCC. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.19.02394","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T20:59:25Z","timestamp":1582664365000},"page":"1138-1145","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":41,"title":["Phase Ib\/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003"],"prefix":"10.1200","volume":"38","author":[{"given":"Arkadiusz Z.","family":"Dudek","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li C.","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore F.","family":"Logan","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Singer","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Joshi","sequence":"additional","affiliation":[{"name":"Penn State Cancer Institute, Pennsylvania State University, State College, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousef N.","family":"Zakharia","sequence":"additional","affiliation":[{"name":"University of Iowa Hospitals and Clinics, University of Iowa, Iowa City, IA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua M.","family":"Lang","sequence":"additional","affiliation":[{"name":"Carbone Cancer Center, University of Wisconsin, Madison, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James K.","family":"Schwarz","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center, Omaha, NE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Al-Janadi","sequence":"additional","affiliation":[{"name":"MSU Breslin Cancer Center, Michigan State University, Lansing, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajjai S.","family":"Alva","sequence":"additional","affiliation":[{"name":"Rogel Cancer Center, University of Michigan, Ann Arbor, MI"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"B1","first-page":"4265","volume":"52","author":"Wu NZ","year":"1992","journal-title":"Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00602.x"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH687>3.0.CO;2-G"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.02954.x"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1215397109"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/8.5.765"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/70932"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.10.5538"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31802e085a"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-012-0284-2"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003689"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0034"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2011.12.009"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09707.x"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.9847"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3078"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30081-0"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021491"},{"key":"B24","volume-title":"the 17th Int Kidney Cancer Sympos","author":"Agarwal N"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30107-4"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30723-8"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.19.02394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T07:17:58Z","timestamp":1653808678000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.19.02394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,10]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,4,10]]}},"alternative-id":["10.1200\/JCO.19.02394"],"URL":"https:\/\/doi.org\/10.1200\/jco.19.02394","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,10]]},"assertion":[{"value":"2020-01-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}